We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

$12 M Grant Supports Flu and Malaria Vaccine Development

$12 M Grant Supports Flu and Malaria Vaccine Development

$12 M Grant Supports Flu and Malaria Vaccine Development

$12 M Grant Supports Flu and Malaria Vaccine Development

Influenza Virus. Credit: PIXNIO
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "$12 M Grant Supports Flu and Malaria Vaccine Development"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists at The Scripps Research Institute aim to improve flu and malaria vaccines with the support of a new $12 million grant from the Bill & Melinda Gates Foundation.

With the funding, the Scripps Research team will expand their studies of antibodies that can neutralize many strains of malaria and influenza. Past Scripps Research studies have shown these “broadly neutralizing antibodies” can serve as guides for designing promising vaccine candidates against influenza, AIDS and other diseases.

The World Health Organization estimates that malaria killed 445,000 people in 2016, the last year when data was reported. Influenza also remains a global killer—up to 650,000 people die each year from seasonal flu.

The grant will be administered by Ian Wilson, DPhil, DSc, Hansen Professor of Structural Biology at Scripps Research and chair of the Department of Integrative Structural and Computational Biology, who has studied influenza since 1977. Wilson and his colleagues have analyzed the structures of possible influenza vaccine candidates with the potential to eliminate the need for an annual flu shot.

“We want to apply the methodologies and expertise that we have accumulated over many years at TSRI for HIV and other pathogens to investigate malaria and help design a more effective and longer lasting flu vaccine,” says Wilson.

Co-leading the study is Dennis Burton, PhD, chair of Scripps Research’s Department of Immunology and Microbiology, and scientific director of the International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and of the National Institutes of Health’s Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID). Co-investigators include professors Andrew Ward, PhD, and William Schief, PhD. The malaria research component of the project is also part of a larger collaboration across several institutions.

“We have a great team here at Scripps Research for rational design of vaccines, and we look forward to taking on malaria and flu with this generous funding from the Gates Foundation,” says Burton.

This article has been republished from materials provided by The Scripps Research Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.